Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in a Series C financing round. The round was led by Kingmed Diagnostics and Guoxin Investment, with contributions from Shenzhen Hi-tech Investment and Venture Capital, Guochuang Zhiyuan, Changzhou Shuangye Venture Capital, and Cai Xin Capital. The funds will be utilized to enhance gene testing equipment and reagents development, expand the product portfolio, increase manufacturing capacity, and support product regulatory filings for both domestic and overseas markets.
Investment in Gene Testing Technology and Expansion
Founded in 2012, GeneMind specializes in single-molecule fluorescence sequencing, which forms the foundation of its GenoCare product line. The company prides itself on its SURFseq sequencing technology system, the world’s first single molecule sequencer approved by the National Medical Products Administration (NMPA) for clinical diagnosis. This financing will further solidify GeneMind’s position in the genetic sequencing space and enable the company to meet the growing demand for advanced gene testing solutions.-Fineline Info & Tech
